Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Microsomal Clearance/Stability

The liver is the major site of drug metabolism in the body, with well over 50% of marketed drugs being eliminated via hepatic mediated metabolism. Hence, measurement of the rate of clearance and the identity of the metabolites of a drug is important. In addition, in support of projects, the rate of clearance values can be used to rank compounds and to predict in vivo hepatic clearance values. Microsomes from a variety of species and tissues can be used to understand inter-species differences and non-hepatic metabolism.

Sygnature’s standard microsomal metabolic stability assay utilises the Phase I cofactor, NADPH. We can also offer a combined Phase I/Phase II assay, utilising NADPH and UDPGA to determine both Phase 1 and Phase 2 (UDP-glucuronosyltransferase (UGT)) metabolism. For the latter, these are accessed by pre-incubating the microsomes with the pore-forming agent, alamethicin.

Sygnature’s microsomal stability assay monitors the disappearance of a compound in the presence and absence of cofactor. All assays are validated by the inclusion of up to 3 species-specific control compounds. Data output consists of mean intrinsic clearance and half-life measurements.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.